Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustments
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Pain, Pain Management, Critical Illness. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustments (INVISIBLE) - an Observational Single-Centre Study in Critically Ill Patients
Overview
Both severe pain and opioid therapy are associated with negative effects. The experience of pain is common in the intensive care unit, but it is highly individual and difficult to assess, as patients are often unable to communicate. This especially applies to patients who are mechanically ventilated. Behavioral assessment tools can help to identify pain in this population, but do not register overdose of opioid therapy. The AlgiScan® delivers the Pupillary Pain Index (PPI), an objective assessment of nociception level, which has been shown to be useful in small studies with respect to reduction of opioid dose without leading to more pain. New institutional protocols for the assessment of pain include the behavioral pain assessment tool Zurich Observational Pain Assessment (ZOPA) and the PPI. This project aims to evaluate the impact of the new institutional protocols on opioid administration and occurrence of pain compared to a historical cohort by analyzing routinely collected data during mechanical ventilation (Part A). In a second part (Part B), promising biomarkers for detection of pain, subjective ratings by nurses and physicians and an additional behavioral pain scale will be evaluated using an observational study design. After screening and enrolment (day 1/visit 1), characteristics of pain will be assessed on 4 occasions during 2 days (day 2/visit 2, day 2/visit 3, day 3/visit 4, day 3/visit 5). On visit 2 and 4, biomarkers (alpha-amylase, cortisol) will be sampled.
Primary outcome measures
- Oral morphine equivalent (OME) per day of mechanical ventilation. [Time frame: Part A: during mechanical ventilation (up to 28 days)]
Secondary outcome measures (12)
- Sufentanil dose per day of mechanical ventilation [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Opioid dose adjustments - Number of adjustments [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Opioid dose adjustments - Relative change during pain assessment [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Zurich Observational Pain Assessment (ZOPA) [Time frame: Part A: during mechanical ventilation Part B: day 2/visit 2, day 2/visit 3, day 3/visit 4, day 3/visit 5]
- Number of rescue analgesics administered per day [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Occurrence of adverse effects of pain per day of mechanical ventilation [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Number of sedatives used per day of mechanical ventilation [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Richmond Agitation Sedation Scale (RASS) < -3 [Time frame: Part A: during mechanical ventilation (up to 28 days)]
- Time to extubation [Time frame: Part A: From time of stop of analgosedation (during mechanical ventilation, up to 28 days) until extubation (up to 7 days). Events such as death or referrals while being intubated will be censored.]
- Opioid prescription at ICU discharge [Time frame: Part A: at ICU discharge assessed up to 5 days]
- Opioid prescription at hospital discharge [Time frame: Part A: at hospital discharge assessed up to 10 days]
- Target nociception level [Time frame: Part A: during mechanical ventilation (up to 28 days)]
Eligibility criteria
Inclusion criteria
Part A
- Admission to the intensive care unit
- Adults (≥18 years) of all sex and gender
- Mechanical ventilation Part B
- Admission to the intensive care unit
- Adults (≥18 years) of all sex and gender
- mechanical ventilation
- Continuous opioid therapy
- Richmond Agitation Sedation Scale (RASS) ≤ -4
- Presumed duration of mechanical ventilation until the end of observations (until day 3)
- Established vascular access suitable for blood sampling independent of study inclusion (arterial line or central venous catheter)
Exclusion criteria
Part A
- None Part B
- Previous enrolment into the current investigation
- Tracheostomy
- Chronic opioid use
- Regional anaesthesia
- Implanted pacemaker device
- Allergy to silicone or ECG-electrodes
- Ophthalmologic disease (e.g. ocular trauma, glaucoma) or past eye surgery
- Fixed pupils
- Known or suspected neurologic disease (including hypoxic encephalopathy)
- Therapy with atropine or topical mydriatics in previous 24 hours or planned
- Therapy with systemic steroids in previous 24 hours or planned
- Therapy with neuromuscular blocking agents in previous 24 hours or planned
- Stomatitis
- Active oral or nasal bleeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- University Hospital Zurich — Zurich
Identifiers
NCT: NCT07473115 · INVISIBLE